ALMKT:EPA
Mauna Kea Technologies SA
0,092 €
0,00%
(0,00) 1 d.
13. nov., 17:35:01 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALMKT…
Atvērt
0,09 €
Augsta
0,10 €
Zema
0,09 €
Tirgus kapitalizācija
18,14 milj.
Vid. apjoms
541,14 tūkst.
Apjoms
75,16 tūkst.
Cenas/peļņas attiecība
0,79
Augstākā 52 ned.
0,23 €
Zemākā 52 ned.
0,07 €
Peļņa uz vienu akciju
0,12 €
Apgrozībā esošās akcijas
195,26 milj.
Darbinieku skaits
56
Atvērt
0,09 €
Augsta
0,10 €
Zema
0,09 €
Tirgus kapitalizācija
18,14 milj.
Vid. apjoms
541,14 tūkst.
Apjoms
75,16 tūkst.
Cenas/peļņas attiecība
0,79
Augstākā 52 ned.
0,23 €
Zemākā 52 ned.
0,07 €
Peļņa uz vienu akciju
0,12 €
Apgrozībā esošās akcijas
195,26 milj.
Darbinieku skaits
56
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
TradingKey
·
pirms 8 stundām
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
The Motley Fool
·
pirms 19 stundām
Prediction: This Small-Cap Value ETF Will Beat the S&P 500 Over the Next 10 Years
TradingView
·
pirms 15 stundām
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
Traders Union
·
pirms 18 stundām
Tom McClellan: NYSE Composite Index better comparison for A-D Line than S&P 500
Profils
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Par “Mauna Kea Technologies SA”
ĢenerāldirektorsSacha Loiseau
Darbinieki56
Dibināšanas datums2000
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietnemaunakeatech.com